Association between high Gal-3 serum levels and worsening of renal function in chronic heart failure outpatients-Reference-Cited by-同舟云学术

Association between high Gal-3 serum levels and worsening of renal function in chronic heart failure outpatients

Published:2019-06 Issue:9 Volume:13 Page:707-713
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Iacoviello Massimo¹^ORCID,Di Serio Francesca²,Rizzo Caterina³,Leone Marta⁴,Grande Dario⁵,Guida Pietro³,Gioia Margherita Ilaria⁵,Parisi Giuseppe⁵,Leopizzi Tiziana⁵,Caldarola Pasquale⁶,Ciccone Marco Matteo⁵,Gesualdo Loreto⁷

Affiliation:

1. University Cardiology Unit, Cardiothoracic Department, Policlinic University Hospital, 70124, Bari, Italy

2. Clinic Pathology Unit, Policlinic University Hospital, 70124, Bari, Italy

3. Division of Cardiology and Cardiac Rehabilitation, Scientific Clinical Institutes Maugeri, IRCCS, Institute of Cassano delle Murge, 70020, Cassano delle Murge, Bari, Italy

4. Cardiology Unit, Santissima Annunziata Hospital, 74100, Taranto, Italy

5. Cardiology Department, Bari Local Health Service, 70123, Bari, Italy

6. School of Cardiology, University of Bari, 70124, Bari, Italy

7. University Nephrology Unit, D.E.T.O., University of Bari, 70124, Bari, Italy

Abstract

Aim: The aim of the study was to evaluate the association between Gal-3 serum levels and the progression of renal dysfunction in chronic heart failure outpatients. Methods & results: This prospective study of 260 chronic heart failure patients showed that Gal-3 was associated with 1-year worsening of renal function both in univariate (odds ratio: 1.12; 95% CI: 1.06–1.18; p < 0.001) and in forward stepwise multivariate (odds ratio: 1.09; 95% CI: 1.03–1.15; p = 0.004) logistic regression analyses. Moreover, high Gal-3 levels at baseline were associated with a progressive decline in the estimated glomerular filtration rate. Conclusion: Gal-3 is a biomarker associated with the progression of renal function decline thus further supporting its possible usefulness in predicting cardiorenal syndrome progression.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2018-0349

Reference22 articles.

1. The role of galectins in the initiation, amplification and resolution of the inflammatory response

2. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

3. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy

4. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

5. Galectin‐3 and Risk of Heart Failure and Death in Blacks and Whites

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers in cardiorenal syndrome, a potential use in precision medicine;Journal of Nephrology;2024-08-17

2. The Need to Identify Novel Markers for Early Renal Injury in Cardiorenal Syndrome;Cells;2024-07-30

3. Association of suPAR, ST2, and galectin-3 with eGFR decline and mortality in patients with advanced heart failure with reduced ejection fraction;Journal of Investigative Medicine;2024-05-22

4. Cardiorenal Syndrome: A Literature Review;Cureus;2023-07-01

5. Renal Assessment in Acute Cardiorenal Syndrome;Biomolecules;2023-01-27